{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:03:32Z","timestamp":1791925412136,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM008562"],"award-info":[{"award-number":["T32GM008562"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1007\/s40261-019-00764-x","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T20:05:59Z","timestamp":1551297959000},"page":"441-451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects"],"prefix":"10.1007","volume":"39","author":[{"given":"Rebecca E.","family":"Wrishko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline B.","family":"McCrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Lai","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Panebianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Mangin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Chakravarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Martinez-Cantarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter K.","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"issue":"2","key":"764_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/bph.12261","volume":"171","author":"CJ Winrow","year":"2014","unstructured":"Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol. 2014;171(2):283\u201393.","journal-title":"Br J Pharmacol."},{"issue":"11","key":"764_CR2","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2174\/156802608784936746","volume":"8","author":"AJ Roecker","year":"2008","unstructured":"Roecker AJ, Coleman PJ. Orexin receptor antagonists: medicinal chemistry and therapeutic potential. Curr Top Med Chem. 2008;8(11):977\u201387.","journal-title":"Curr Top Med Chem."},{"key":"764_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1146\/annurev-pharmtox-010716-104837","volume":"57","author":"PJ Coleman","year":"2017","unstructured":"Coleman PJ, Gotter AL, Herring WJ, Winrow CJ, Renger JJ. The discovery of suvorexant, the first orexin receptor drug for insomnia. Annu Rev Pharmacol Toxicol. 2017;57:509\u201333.","journal-title":"Annu Rev Pharmacol Toxicol."},{"issue":"3","key":"764_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1124\/pr.111.005546","volume":"64","author":"AL Gotter","year":"2012","unstructured":"Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology. Pharmacol Rev. 2012;64(3):389\u2013420.","journal-title":"Pharmacol Rev."},{"issue":"7","key":"764_CR5","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1046\/j.0953-816x.2001.01725.x","volume":"14","author":"Y Yoshida","year":"2001","unstructured":"Yoshida Y, Fujiki N, Nakajima T, Ripley B, Matsumura H, Yoneda H, et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci. 2001;14(7):1075\u201381.","journal-title":"Eur J Neurosci."},{"key":"764_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","volume":"51","author":"TE Scammell","year":"2011","unstructured":"Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011;51:243\u201366.","journal-title":"Annu Rev Pharmacol Toxicol."},{"issue":"4","key":"764_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","volume":"92","author":"T Sakurai","year":"1998","unstructured":"Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573\u201385.","journal-title":"Cell."},{"key":"764_CR8","unstructured":"Merck Sharp & Dohme Corp. Belsomra (suvorexant) Package Insert. 2014. http:\/\/www.merck.com\/product\/usa\/pi_circulars\/b\/belsomra\/belsomra_pi.pdf. Accessed 26 June 2018."},{"key":"764_CR9","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1089\/cap.2016.0206","volume":"27","author":"K Kawabe","year":"2017","unstructured":"Kawabe K, Horiuchi F, Ochi M, Nishimoto K, Ueno SI, Oka Y. Suvorexant for the treatment of insomnia in adolescents. J Child Adolesc Psychopharmacol. 2017;27:792\u20135.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"23","key":"764_CR10","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","volume":"79","author":"WJ Herring","year":"2012","unstructured":"Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79(23):2265\u201374.","journal-title":"Neurology."},{"issue":"2","key":"764_CR11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","volume":"79","author":"WJ Herring","year":"2016","unstructured":"Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79(2):136\u201348.","journal-title":"Biol Psychiatry."},{"issue":"7","key":"764_CR12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jagp.2017.03.004","volume":"25","author":"WJ Herring","year":"2017","unstructured":"Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, et al. Suvorexant in elderly patients with insomnia: pooled analyses of data from Phase III randomized controlled clinical trials. Am J Geriatr Psychiatry. 2017;25(7):791\u2013802.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"5","key":"764_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","volume":"13","author":"D Michelson","year":"2014","unstructured":"Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a Phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461\u201371.","journal-title":"Lancet Neurol."},{"issue":"2","key":"764_CR14","first-page":"259","volume":"36","author":"H Sun","year":"2013","unstructured":"Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013;36(2):259\u201367.","journal-title":"Sleep."},{"issue":"(Abstract Suppl","key":"764_CR15","first-page":"pA226","volume":"35","author":"A Vermeeren","year":"2012","unstructured":"Vermeeren A, Vuurman E, Bautmans A, Li X, Vets E, Lewis N, et al. Suvorexant, a dual orexin receptor antagonist, does not impair next day driving performance in healthy elderly subjects. Sleep. 2012;35(Abstract Supplement):pA226 (Abstract 0670).","journal-title":"Sleep."},{"issue":"Suppl 1","key":"764_CR16","first-page":"S320","volume":"38","author":"A Vermeeren","year":"2012","unstructured":"Vermeeren A, Vuurman E, Van Oers A, Van Leeuwen C, Jongen S, Bautmans A, et al. Effects of suvorexant, an orexin receptor antagonist on next day driving performance in healthy non-elderly subjects. Neuropsychopharmacology. 2012;38(Suppl 1):S320\u20131.","journal-title":"Neuropsychopharmacology."},{"key":"764_CR17","unstructured":"U.S. Food and Drug Administration. Clinical Drug Interaction Studies \u2014 Study Design, Data Analysis, and Clinical Implications Guidance for Industry DRAFT GUIDANCE. 2017. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM292362.pdf. Accessed 28 June 2018."},{"key":"764_CR18","unstructured":"RxList. Ambien (zolpidem) Package Insert. 2004. https:\/\/www.rxlist.com\/ambien-drug\/patient-images-side-effects.htm. Accessed 29 June 2018."},{"key":"764_CR19","unstructured":"Sunovion Pharmaceuticals Inc. Lunesta [package insert]. 2014. http:\/\/www.lunesta.com\/PostedApprovedLabelingText.pdf. Accessed 29 June 2018."},{"issue":"10","key":"764_CR20","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3109\/00498254.2015.1129565","volume":"46","author":"D Cui","year":"2016","unstructured":"Cui D, Cabalu T, Yee KL, Small J, Li X, Liu B, et al. In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans. Xenobiotica. 2016;46(10):882\u201395.","journal-title":"Xenobiotica."},{"key":"764_CR21","unstructured":"U.S. Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. 2018. https:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/developmentresources\/druginteractionslabeling\/ucm093664.htm. Accessed 3 July 2018."},{"issue":"3","key":"764_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0009-9236(98)90172-2","volume":"64","author":"DJ Greenblatt","year":"1998","unstructured":"Greenblatt DJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, et al. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther. 1998;64(3):237\u201347.","journal-title":"Clin Pharmacol Ther."},{"issue":"1","key":"764_CR23","first-page":"294","volume":"282","author":"D Sutton","year":"1997","unstructured":"Sutton D, Butler AM, Nadin L, Murray M. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther. 1997;282(1):294\u2013300.","journal-title":"J Pharmacol Exp Ther."},{"issue":"9","key":"764_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","volume":"42","author":"M Niemi","year":"2003","unstructured":"Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet. 2003;42(9):819\u201350.","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"764_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0009-9236(97)90176-4","volume":"61","author":"K Villikka","year":"1997","unstructured":"Villikka K, Kivisto KT, Backman JT, Olkkola KT, Neuvonen PJ. Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther. 1997;61(1):8\u201314.","journal-title":"Clin Pharmacol Ther."},{"issue":"6","key":"764_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0009-9236(97)90082-5","volume":"62","author":"K Villikka","year":"1997","unstructured":"Villikka K, Kivisto KT, Luurila H, Neuvonen PJ. Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther. 1997;62(6):629\u201334.","journal-title":"Clin Pharmacol Ther."},{"issue":"1","key":"764_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0009-9236(96)90018-1","volume":"59","author":"JT Backman","year":"1996","unstructured":"Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther. 1996;59(1):7\u201313.","journal-title":"Clin Pharmacol Ther."},{"issue":"4","key":"764_CR28","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/0091270008331133","volume":"49","author":"SA Stoch","year":"2009","unstructured":"Stoch SA, Friedman E, Maes A, Yee K, Xu Y, Larson P, et al. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm. J Clin Pharmacol. 2009;49(4):398\u2013406.","journal-title":"J Clin Pharmacol."},{"issue":"11","key":"764_CR29","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1177\/0091270010387141","volume":"51","author":"EJ Friedman","year":"2011","unstructured":"Friedman EJ, Fraser IP, Wang Y-H, Bergman AJ, Li C-C, Larson PJ, et al. Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go? J Clin Pharmacol. 2011;51(11):1561\u201370.","journal-title":"J Clin Pharmacol."},{"issue":"4","key":"764_CR30","first-page":"332","volume":"9","author":"H Sun","year":"2011","unstructured":"Sun H, Kennedy WD, Lewis N, Laethem T, Tee K, Li X, et al. The single dose pharmacokinetic (PK) and pharmacodynamic (PD) profiles of suvorexant (MK-4305), a dual orexin receptor antagonist, in healthy male subjects. Sleep Biol Rhythms. 2011;9(4):332 (Abstract).","journal-title":"Sleep Biol Rhythms."},{"issue":"5","key":"764_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/clpt.1994.60","volume":"55","author":"KT Olkkola","year":"1994","unstructured":"Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994;55(5):481\u20135.","journal-title":"Clin Pharmacol Ther."},{"issue":"6 Pt 1","key":"764_CR32","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/clpt.1994.184","volume":"56","author":"A Varhe","year":"1994","unstructured":"Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994;56(6 Pt 1):601\u20137.","journal-title":"Clin Pharmacol Ther."},{"key":"764_CR33","first-page":"89","volume":"36","author":"T Kronbach","year":"1989","unstructured":"Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrom P450IIIA4. Mol Pharmacol. 1989;36:89\u201396.","journal-title":"Mol Pharmacol."},{"key":"764_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jchromb.2015.07.056","volume":"1002","author":"SA Breidinger","year":"2015","unstructured":"Breidinger SA, Simpson RC, Mangin E, Woolf EJ. Determination of suvorexant in human plasma using 96-well liquid-liquid extraction and HPLC with tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;1002:254\u20139.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"issue":"7","key":"764_CR35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s40261-018-0650-4","volume":"38","author":"KL Yee","year":"2018","unstructured":"Yee KL, McCrea J, Panebianco D, Liu W, Lewis N, Cabalu T, et al. Safety, tolerability, and pharmacokinetics of suvorexant: a randomized rising-dose trial in healthy men. Clin Drug Invest. 2018;38(7):631\u20138.","journal-title":"Clin Drug Invest."},{"key":"764_CR36","unstructured":"Drugs.com. Sonata (zaleplon) Package Insert. 2004. https:\/\/www.drugs.com\/sonata.html. Accessed 3 July 2018."}],"updated-by":[{"DOI":"10.1007\/s40261-019-00777-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-019-00764-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00764-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00764-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:18:48Z","timestamp":1627690728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-019-00764-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,1]]}},"alternative-id":["764"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00764-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40261-019-00777-6","asserted-by":"object"}]},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,27]]},"assertion":[{"value":"27 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-019-00777-6","URL":"https:\/\/doi.org\/10.1007\/s40261-019-00777-6","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"These trials and medical writing support was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"REW, JBM, KLY, WL, DP, EM, and MC are current or former employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and may own stock and\/or stock options. MPM-C was supported by National Institutes of Health Postdoctoral Training Grant No. T32GM008562. WKK has no disclosure to make.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human subjects were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual subjects included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}